Odylia Therapeutics, a nonprofit biotechnology company dedicated to advancing treatments for rare diseases, today announced the appointment of Wendy Erler to its Board of Directors. Erler brings more than two decades of leadership experience across patient advocacy, rare disease strategy, medical affairs, and commercialization in the biopharmaceutical industry.

Erler currently serves as Senior Vice President of Patient Affairs at Sarepta, where she is a member of the executive leadership team. In this role, she bridges customer and company strategy to ensure patient-centricity across the organization, embedding the patient voice throughout the product lifecycle, from clinical trials to commercialization. She is widely recognized for her ability to build collaborative cultures and translate patient insight into meaningful action across complex organizations.

“Wendy’s leadership and deep commitment to patients make her an incredible addition to Odylia’s Board,” said Ashley Winslow, CEO & CSO at Odylia Therapeutics. “She has consistently championed approaches that place patients at the center of innovation. Her experience and perspective will help guide our work to advance treatments for people living with rare diseases that are often overlooked.”

Prior to joining Sarepta, Erler served at Alexion, AstraZeneca Rare Disease, where she led the Global Patient Experience function. In that role, she developed and implemented an enterprise-wide model to integrate patient insights across the business, establishing governance frameworks and metrics that enabled the organization to scale and measure its patient-focused initiatives. She also served on the Human Resources and Global Medical Affairs leadership teams.

Known for her authentic commitment to patients and her ability to connect communities with critical resources and services, Erler has built strong partnerships across advocacy organizations, healthcare providers, policymakers, and industry stakeholders.

“I’m honored to join the Odylia Therapeutics Board of Directors,” said Erler. “Odylia is tackling some of the most difficult challenges in rare disease by creating new business models to develop treatments for conditions that might otherwise be overlooked. I’m excited to support the organization’s mission and help ensure that patient perspectives remain central to its work.”

Erler earned her bachelor’s degree from Miami University and holds an MBA from Saint Joseph’s University.

—

Media Contact:

For media inquiries, please contact:
Odylia Media
info@odylia.org

About Odylia Therapeutics

Odylia Therapeutics is a nonprofit biotechnology company dedicated to developing and advancing treatments for rare diseases. Through deep drug development expertise, innovative research, strategic collaborations, and patient-focused initiatives, Odylia works to overcome barriers to treatment development and bring new hope to patients around the world. Odylia partners with patient communities, researchers, clinicians, industry, and financial donors to bring promising therapeutics to clinical trials. In addition to three gene therapies in development, Odylia partners with rare disease patient groups, early-stage biotechs, and academic researchers to further rare disease drug development efforts through Odylia’s Brydge Solutions program. Patient groups, companies, and researchers interested in learning more about Odylia Therapeutics’ services can email info@odylia.org and follow Odylia on LinkedIn (Odylia Therapeutics), Instagram (@OdyliaTx), and YouTube (@OdyliaTx). For additional information, visit https://odylia.org.